John W. Hayslip

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Kieron Dunleavy, Michelle A. Fanale, Ariela Noy et al. · The Lancet Haematology · 2018 · 232 citations

Medicine, Oncology, Pharmacology +11

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Kieron Dunleavy, Michelle A. Fanale, Ann S. LaCasce et al. · Blood · 2014 · 55 citations

Medicine, Hematology, Oncology +9

Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia.

Tara L. Lin, Stephen A. Strickland, Walter Fiedler et al. · Journal of Clinical Oncology · 2016 · 35 citations

Medicine, Pharmacology, Pharmacotherapy +16

Cost-Effectiveness of Extended Adjuvant Rituximab for US Patients Aged 65–70 Years with Follicular Lymphoma in Second Remission

John W. Hayslip, Kit N. Simpson · Clinical Lymphoma & Myeloma · 2008 · 25 citations

Pharmacy, Oncology, Pharmacoeconomics +8

Decision Making and Distress Among Individuals Diagnosed with Follicular Lymphoma

Jennifer Kilkus Poe, John W. Hayslip, Jamie L. Studts · Journal of Psychosocial Oncology · 2012 · 16 citations

Social Sciences, Oncology, Psychology +15